Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6738 in MDS or CMML Progressing on Front-Line Therapy
NCT03770429Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2019
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ceralasertib in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Massachusetts General Hospital. Primary endpoint: Incidence of dose limiting toxicities at 2 years. Started Aug 2019; status: active, not recruiting.
02
Drugs
ceralasertib
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03770429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770429.